openPR Logo
Press release

Generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market

07-24-2018 10:12 AM CET | Health & Medicine

Press release from: Future Market Insights

Generic and branded anticonvulsants are restraining the growth

Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used in treatment of bipolar disorder and in neuropathic pain management.

Anyone could potentially have a single epileptic seizure at some point in their lives. This is not the same as having epilepsy, which is a tendency to have seizures that start in the brain. Epilepsy can affect people of any age group. Though brain injury, brain cancer, drug and alcohol misuse and stroke are some of the reasons for epileptic seizures, the exact reason for convulsions is not known. Some of the common symptoms which occur before convulsions include, visual loss, strange feeling, nausea, numbness in body parts, headache and racing thoughts.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1337

Anticonvulsants Market: Drivers and Restraints

Increasing awareness about the anticonvulsants available in the market, patent expiration of many blockbuster drugs are some of the major factors that are driving the global anticonvulsants market towards growth. There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the US by FDA. Moreover, three trends involving consumption of AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. While, high costs and unavailability of convenient dosage forms of both generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market.

Anticonvulsants Market: Segmentation

Anticonvulsants market is segmented based on product type, application, end user and geography.

Based on product type, the anticonvulsants market is segmented as follows:

Barbiturates

Aldehydes

Benzodiazepines

Aromatic allylic alcohols

Carboxamides

Bromides

Carbamates

Sulfonamides

Fructose derivatives

Pyrrolidines

Triazines

Fatty acids

Oxazolidinediones

Ureas

GABA analogs

Propionates

Hydantoins

Pyrimidinediones

Valproylamides (amide derivatives of valproate)

Others

Based on application, the anticonvulsants market is segmented as follows:

Epilepsy

Fibromyalgia

Migraine

Neuropathic pain

Bipolar disorder

Anxiety

Borderline personality disorder

Based on end user, the anticonvulsants market is segmented as follows:

Hospitals

Clinics

Ambulatory surgical clinics

Anticonvulsants Market: Overview

Seizures are expected to result in physical, psychological and social repercussions. People with epilepsy could adhere rigorously to their medication regimes in order to prevent these deleterious outcomes. Treatment of epileptic seizures has led to the growth of anticonvulsants market. Barbiturates were the first antiepileptic drugs. These are more effective and tolerable than bromides. Hydantoins are the first to be known as modern antiepileptic drugs. Succinimides are an old group of drug which are rarely prescribed nowadays. Consequently with these antiepileptic or antiseizure drugs, anticonvulsants market is growing immensely leaving a significant impact on the treatment of epileptic seizures. The antiepileptic drug market is threatened by generic completion, which has been increasing dramatically in the face of patent expirations among several of the major branded antiepileptics. However, there have been cases where generic antiepileptic drugs have not been as efficacious as their branded counterparts have.

Anticonvulsants Market: Region-wise Outlook

Region wise, the global anticonvulsants marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Currently, North America dominates the anticonvulsants market followed by Europe. Asia-Pacific is expected to emerge as a lucrative region, owing to factors such as increasing healthcare spending, improving healthcare infrastructure, and increasing demand for drugs. Given these factors, the market for anticonvulsants is likely to grow rapidly in Asia-Pacific region.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-1337

Anticonvulsants Market: Key Players

Some of the key players, contributing to global anticonvulsants drug market, are Johnson & Johnson (J&J), Novartis AG, UCB Group, GlaxoSmithKline plc, Pfizer Inc., Abbott Laboratories, Cephalon Inc. and Shire plc. Pfizer has been estimated to cover the largest market share in the antiepileptic market, accounting for close to one-third of total revenues of the market with it two leading brands.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web:https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market here

News-ID: 1142008 • Views: 187

More Releases from Future Market Insights

Ferrovanadium Market to Witness Robust Expansion throughout the Forecast 2018-20 …
Future Market Insights (FMI) analyses the global ferrovanadium market in its new publication titled “Ferrovanadium Market: Global Industry Analysis (2013 – 2017) & Opportunity Assessment (2018 – 2028)”. This study provides data for 2017 along with the forecast for the period (2018–2028). The main objective of the report is to identify the dynamics of the market and provide recent updates and insights pertaining to various segments of the global ferrovanadium
Automotive Lighting Market is expected to grow at a CAGR of ~6% during the forec …
In a recent publication, Future Market Insights (FMI) provides a perspective on the growth trajectory of automotive lighting market for the period between 2019 and 2029. According to the study, worldwide sales of automotive lighting reached ~2 billion units, equating a value of ~US$ 36.5 billion in 2018. Gains remain driven by growing popularity of luxury cars and high purchasing power of middle class demographic in developing countries that increased the
Motorcycle Suspension System Market Size, Share, Industry Analysis, Future Growt …
Future Market Insights has released a new market study on "Motorcycle Suspension System Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028", which studies the global Motorcycle Suspension System market and offers deep dive analysis for the next ten years. The report evaluates all the key macro-economic factors projected to support the growth of the global as well as regional markets. The report on Motorcycle Suspension System also presents the
Clinical Trials Market Survey Report 2021 Along with Statistics, Forecasts till …
The study offers a long-term forecast of the clinical trials landscape for the period between 2019 and 2029. The clinical trials landscape is projected to record a 4.5% CAGR through 2029. Collaboration at Its Peak: Key Strategy of Manufacturers in Clinical Trials Market For reducing economic burden, many companies are planning to shift their focus towards on-core business activities, thereby outsourcing their clinical trials activities to the CROs (contract research organizations). This

All 5 Releases


More Releases for Anticonvulsants

Anticonvulsants Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Anticonvulsants Market” report will be very useful to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, SWOT analysis, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts. The Anticonvulsants market was valued at
Epileptic Anticonvulsants Market Size, Growth, Trends and 2020 Forecast Report
According to the WHO, nearly 80% of epilepsy patients are found in developing regions. However, developed regions are dominant in the global epileptic anticonvulsants market. Currently, North America dominates the epileptic anticonvulsants market, followed by Europe. Highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy and related treatments, along with availability of skilled professionals to treat epilepsy are driving the North America and Europe epileptic anticonvulsants
Anticonvulsants for Neuropathic Pain Market unprovoked by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants for Neuropathic Pain Market Business Strategy & Forecast by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants Drug Market - Significant Growth During 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and
Anticonvulsants Drug Market Research Report by Key Players Analysis 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and